Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renshenguben Oral Liquid for Cancer-Related Fatigue
ChiCTR2100044250Phase 4Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Apr 2021
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Renshen Guben in cancer-related fatigue (CRF) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Change in Brief Fatigue Inventory (BFI) score at 6 weeks vs baseline. Started Apr 2021; status: recruiting.
02
Drugs
Renshen Guben
03
Conditions
cancer-related fatigue (CRF)
Beyond the preview
Go deeper on ChiCTR2100044250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044250.